Clinical trials
Colitis clinical trials
Below are recruiting colitis clinical trials, each written for real people, not researchers. We’re tracking 320 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07758335RecruitingPhase 4
Probiotics and trace elements for ulcerative colitis
This trial tests whether adding a probiotic supplement and trace elements to your current treatment helps manage mild to moderate ulcerative colitis. It aims to see if these additions can improve symptoms and quality of life.
CairoAges 18–65 - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Peoria, ArizonaAges 16–80 - NCT07726888Recruiting
Guselkumab for moderate-to-severe ulcerative colitis
This study tests a drug called Guselkumab (already approved for other conditions) for treating moderate to severe ulcerative colitis. It aims to see how safe and effective the drug is in real-world patients who have not had success with other treatments.
Wenzhou, ZhejiangAges 18 years+ - NCT07686081RecruitingPhase 3
Testing ponesimod for moderate to severe ulcerative colitis
This trial tests an oral medication called ponesimod for people with ulcerative colitis that hasn't responded well to other treatments. It aims to see if ponesimod can reduce inflammation and improve symptoms.
Chula Vista, CaliforniaAges 18–75 - NCT07136116Recruiting
Study of risankizumab for moderate to severe ulcerative colitis in Japan
This study looks at how well risankizumab (an injected medicine) works for people with moderate to severe ulcerative colitis. It tracks your symptoms using a mobile app to see if the drug helps control the disease.
Nagakute, Aichi-kenAges 15 years+ - NCT07158242RecruitingPhase 3
Study of afimkibart for children with active ulcerative colitis
This study tests a new drug called afimkibart in children with moderate to severe ulcerative colitis who haven't responded well to other treatments. It aims to see how well the drug works and if it's safe for children.
Aurora, ColoradoAges 2–17 - NCT06095128RecruitingPhase 4
Vedolizumab and tofacitinib study for ulcerative colitis
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
Dothan, AlabamaAges 18–65 - NCT06372613Recruiting
LRG protein and ulcerative colitis remission
This study looks at a protein called LRG in your blood or tissue to see if it can tell if your ulcerative colitis is in remission (quiet or not active). This might help doctors better monitor and treat UC in the future.
KomaganeAges 20–90 - NCT05867329RecruitingPhase 4
Comparing treatments for severe ulcerative colitis flare-ups
This study compares different sequences of medicines for treating severe ulcerative colitis flares in the hospital. It aims to find the best way to get your symptoms under control and help you feel better faster.
Ann Arbor, MichiganAges 18–75 - NCT07636304Enrolling by invitationEarly Phase 1
Brain stimulation for inflammatory bowel disease remission
This study tests whether a non-invasive device that stimulates the vagus nerve (a major nerve in your neck) can affect brain function in people whose IBD is in remission. Researchers want to understand if this stimulation might help reduce inflammation or improve symptoms in the future.
Gdansk, Pomeranian VoivodeshipAges 18 years+ - NCT00001184Recruiting
Studying the immune system in Crohn's and colitis
This study collects blood and tissue samples to better understand how the immune system behaves in people with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. It aims to advance research rather than test a specific new treatment, and it also enrolls healthy volunteers for comparison.
Bethesda, MarylandAges 1 day–75 years - NCT07752446Recruiting
Mediterranean diet and time-restricted eating for ulcerative colitis
This study tests whether following a Mediterranean diet and limiting eating to a certain time window each day can help maintain remission in people with ulcerative colitis. It aims to see if this lifestyle change can keep the condition from flaring up.
Santiago, Santiago MetropolitanAges 18–60 - NCT04373473RecruitingPhase 2
Oral stool treatment to prevent ulcerative colitis flare-ups
This study tests whether taking freeze-dried (lyophilized) donor stool material by mouth can help prevent ulcerative colitis from coming back or causing intestinal inflammation. Participants are in remission and stay on their usual treatment while receiving the study product.
Houston, TexasAges 18 years+ - NCT07483073RecruitingPhase 2
Study of new drugs for moderate to severe ulcerative colitis or Crohn's disease
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Scottsdale, ArizonaAges 18–80 - NCT04926103Recruiting
Fecal transplant program for active ulcerative colitis donors
This trial screens people as potential donors for a fecal microbiota transplant program used for ulcerative colitis. It checks safety and eligibility so the transplant process is as safe as possible for people with active disease.
Hamilton, OntarioAges 18 years+ - NCT07546097RecruitingPhase 4
Upadacitinib vs Steroids for Severe Ulcerative Colitis
This study compares a newer medication called upadacitinib to traditional steroids for treating acute severe ulcerative colitis (sudden worsening of UC with bloody diarrhea and urgent symptoms). The goal is to see which approach works better as a first treatment.
Ankang, ShaanxiAges 18–85 - NCT07550673RecruitingPhase 4
Upadacitinib vs. Infliximab for Severe Ulcerative Colitis
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
Ankang, ShaanxiAges 18–85 - NCT05786404RecruitingPhase 1
Fecal transplant study for people with active ulcerative colitis
This trial tests whether transplanting stool bacteria (called fecal microbiota transplantation, or FMT) can improve symptoms in people with active ulcerative colitis. You may be able to help test a new approach for restoring gut bacteria, while receiving standard ulcerative colitis care from your doctor.
Houston, TexasAges 18 years+ - NCT06588855RecruitingPhase 3
Study of afimkibart for moderate to severe ulcerative colitis
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
Dothan, AlabamaAges 16–80 - NCT07258771RecruitingPhase 4
Upadacitinib plus steroids vs steroids alone for severe ulcerative colitis
This trial tests if adding upadacitinib (a pill) to standard steroid treatment helps people with a severe flare of ulcerative colitis feel better faster. You may qualify if you are having frequent bloody stools and signs of serious inflammation, and you haven't tried upadacitinib before.
Ann Arbor, MichiganAges 18–75 - NCT07237516Recruiting
Study of Zymfentra for people with Crohn's or colitis
This study follows adults with inflammatory bowel disease who are starting or switching to Zymfentra. Researchers will track your health over the next year to see how the medicine works in real life.
New Haven, ConnecticutAges 18 years+ - NCT06100289RecruitingPhase 3
Study of vedolizumab for kids with ulcerative colitis or Crohn's disease
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
Phoenix, ArizonaAges 2–17 - NCT07442045Recruiting
Comparing combined vs single drug for ulcerative colitis
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
Foshan, GuangdongAges 18 years+ - NCT07606339Recruiting
Guselkumab for moderate-to-severe Crohn's or ulcerative colitis
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
ViennaAges 18 years+
Hear when a new Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colitis?
- Yes. Clin2 currently lists 320 recruiting colitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.